# Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

> **NCT00313014** · PHASE3 · TERMINATED · sponsor: **Purdue Pharma LP** · enrollment: 660 (actual)

## Conditions studied

- Back Pain Lower Back Chronic

## Interventions

- **DRUG:** Buprenorphine
- **DRUG:** Buprenorphine
- **DRUG:** Oxycodone Immediate-Release

## Key facts

- **NCT ID:** NCT00313014
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 660 (ACTUAL)
- **Why stopped:** Terminated early due to administrative reasons unrelated to efficacy or safety.
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313014, "Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00313014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*